Background
==========

Alzheimer disease (AD) is one of the most prevalent health problems among seniors. It is a chronic neurodegenerative disease characterized by progressive cognition impairment and short-term memory loss, which usually deteriorates with aging. Amyloid plaques and neurofibrillary tangles are identified as 2 hallmarks in the AD process \[[@b1-medscimonit-22-1924]\].

The amyloid cascade hypothesis is one of the most influential hypotheses regarding AD pathogenesis. It suggests that the initial pathological event in AD is triggered by deposition of amyloid β (Aβ) in the brain, which further leads to the formation of tau-immunoreactive neurofibrillary tangles (NFT), extracellular senile plaques (SP), neuron dysfunction, and neuronal loss \[[@b2-medscimonit-22-1924]\]. Aβ peptides are cut from amyloid precursor protein (APP) by secretases and aggregate to form oligomers. The malformation of oligomers or the dysfunction of oligomers further break down enzymes, leading to amyloid plaques and neurofibrillary tangles and triggering the process of AD. Tau as a microtubules-associated protein is also suspected to play an important part in the progression of AD, and was found to be the major constituent of neurofibrillary tangles. According to the amyloid cascade hypothesis, formation of the insoluble aggregates of tau is triggered by increased Aβ level via the induced hyperphosphorylation of tau \[[@b3-medscimonit-22-1924]\]. In contrast, in the tau hypothesis it is the tau protein abnormality that is thought to trigger the disease \[[@b4-medscimonit-22-1924]\]. Another important hypothesis regarding the pathogenesis of AD is the acetylcholine hypothesis; it is also the basis of most currently available AD drugs. According to this theory, AD is caused by reduced synthesis of the neurotransmitter acetylcholine (ACh) \[[@b5-medscimonit-22-1924]\], and, by external supplementation of ACh, the symptoms of AD can be reduced.

Aside from cells, the mitochondrial cascade hypothesis indicates that critical changes in mitochondrial function initiate other pathologies characteristic of AD. Accumulation of amyloid-β (Aβ) causes mitochondrial dysfunction in AD, leading to decreased ATP levels and increased ROS generation. It can also enhance mitochondrial dysfunction and apoptosis, and inhibit protein import inside the mitochondria. Mitochondrial DNA mutations and mitochondrial DNA damage are also involved in the pathogenesis of AD. Phosphorylated tau and Aβ can lead to increased mitochondrial fission and neurodegeneration. Aβ and APP impair mitochondrial fusion/fission processes, mitophagy, and mitochondrial movement, and cause abnormal morphology \[[@b6-medscimonit-22-1924]\].

In addition to the various AD hypotheses, many genes involved in the pathway are suspected to be risk factors of AD, including *APP*, *APOE*, *CASS4*, and *CELF1* \[[@b7-medscimonit-22-1924]\]. Although the association of AD with some genes has been verified by many studies, the contradictions between different studies make it difficult to form firm conclusions about such associations. Therefore, we performed a meta-analysis of published studies to investigate the correlation between suspected genes and AD susceptibly.

*CHAT* (choline O-acetyltransferase) gene encodes an enzyme that catalyzes the biosynthesis of ACh. The enzyme is also characteristic of cholinergic neurons, and changes in these neurons may contribute to some AD symptoms. The A allele of *CHAT* c.2384G\>A polymorphism was also associated with earlier onset and possibly accelerated progression of AD \[[@b8-medscimonit-22-1924]\]. *CHAT* was considered as a suspected gene in this meta-analysis.

*TFAM* (transcription factor A, mitochondrial) gene encodes a key mitochondrial transcription factor that functions in mitochondrial DNA replication and repair. Impaired expression of *TFAM* may influence the function of mitochondria and thus lead to AD.

Another suspected gene in this study is *VR22* (also known as CTNNA3, catenin \[cadherin-associated protein\], alpha 3). The encoded protein plays a role in cell-cell adhesion. The association between *VR22* and AD was first reported in several linkage studies \[[@b9-medscimonit-22-1924]--[@b12-medscimonit-22-1924]\]. Further studies also provided evidence of significant interaction between *APOE-4* and *VR22* SNPs \[[@b13-medscimonit-22-1924]\], indicating that *VR22* or a nearby gene may influence susceptibility to AD.

We conducted a meta-analysis of studies concerning *CHAT*, *TFAM,* and *VR22* polymorphisms and AD susceptibility to further understand the pathogenesis of AD.

Material and Methods
====================

Search strategy
---------------

In the current study, PubMed/Medline, Embase, Web of Science, the Cochrane Library, and Google Scholar were searched with related terms (details shown in [Supplemenatry Table 1](#s1-medscimonit-22-1924){ref-type="supplementary-material"}). Articles published prior to August 2015 were searched for potential SNP targets. References of retrieved articles were manually checked for other relevant publications.

Study selection and data extraction
-----------------------------------

The following criteria had to satisfied by eligible studies: (a) case-control studies covering the association between SNPs on *CHAT*, *TFAM,* or *VR22* genes and susceptibility to AD; (b) sufficient requirements for estimating odds ratios (ORs) and their 95% confidence interval (CIs) must have been satisfied; (c) the diagnosis of AD was confirmed by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) criteria \[[@b14-medscimonit-22-1924]\] published by the American Psychiatric Association, or the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) -- the Alzheimer's Disease and Related Disorders Association (ADRDA) Alzheimer's Criteria \[[@b15-medscimonit-22-1924]\]. Studies were excluded if they were: (a) not a case-control study; (b) had insufficient data provided; (c) were cited by a previous meta-analysis of same subject. The name of first author, publication year, country of origin, ethnicities of subjects, studied SNPs and genes, number of subjects, frequencies of allele and genotype, and indication of Hardy-Weinberg equilibrium (HWE) in the controls were documented for each study. Ethnicity was categorized as white or Asian. No study was conducted in African populations. Four SNPs for *CHAT* gene (rs1880676, rs2177369, rs3810950, and rs868750); 2 SNPs for *TFAM* gene (rs1937 and rs2306604); and 2 SNPs for *VR22* gene (rs10997691 and rs7070570) were included in this meta-analysis. Data from retrieved studies were independently extracted by 2 reviewers. In cases of conflicting evaluations, 2 of the authors discussed the issues to reach a consensus; if no agreement could be reached, a third author would decide.

Statistical analysis
--------------------

The strength of associations between the studied SNPs and susceptibility to AD were assessed by OR corresponding to 95% CI. Four genetic models (the allele, the dominant, the recessive, and the homozygous) were examined. A 2-sided *P*\<0.05 in the Z test was considered as statistically significant. Subgroup analyses were performed by ethnicity (Asian/white). Heterogeneities were tested with Cochran's Q-statistic \[[@b16-medscimonit-22-1924]\] with a *P~h~*\>0.05 indicating lack of heterogeneity. Mantel-Haenszel (M-H) method for the fixed-effects model \[[@b17-medscimonit-22-1924]\] was used to calculate the pooled OR estimate of studies without heterogeneity; otherwise, the DerSimonian and Laird (D-L) method \[[@b18-medscimonit-22-1924]\] was used for the random-effects model. A funnel plot was used to detect publication bias. The standard error of log (OR) of each study was plotted against its log (OR) in the plot. Possible funnel plot asymmetry was evaluated by Egger's linear regression test on the natural logarithm scale of OR \[[@b19-medscimonit-22-1924]\]. All statistical analyses were performed with STATA version 12.0 software (Stata Corp, College Station, TX), using 2-sided *P*-values.

Results
=======

Study characteristics
---------------------

In the search for *CHAT* gene polymorphisms and AD association, we retrieved 26 articles \[[@b8-medscimonit-22-1924],[@b20-medscimonit-22-1924]--[@b44-medscimonit-22-1924]\] from PubMed/Medline, Embase, Web of Science, the Cochrane Library, and Google Scholar, with 28 studies related to rs1880676, rs2177369, rs3810950, and rs868750. For *TFAM* gene polymorphisms, 10 articles and 11 studies were enrolled. For *VR22*, 4 articles and 12 studies were enrolled. A total of 51 case-control studies were included in our meta-analysis, with 16 446 cases and 16 057 controls. The details of methodological and characteristics qualities of the eligible studies are compiled in [Supplementary Table 2](#s2-medscimonit-22-1924){ref-type="supplementary-material"}.

*CHAT* gene polymorphisms correlated with AD risk
-------------------------------------------------

Among the studied SNPs, rs2177369 (G\>A) and rs3810950 (G\>A) were found to be associated with AD susceptibility, but no association was detected between rs1880676 and rs868750 and AD risk ([Figures 1](#f1-medscimonit-22-1924){ref-type="fig"}, [2A](#f2-medscimonit-22-1924){ref-type="fig"}). As shown in [Table 1](#t1-medscimonit-22-1924){ref-type="table"}, rs2177369 (G\>A) was a risk factor for AD onset (OR=1.61, 95% CI=1.07--2.43, *P*=0.022). For rs3810950 (G\>A), a mutation is a risk factor for AD (OR=1.79, 95% CI=1.12--2.86, *P=*0.016, [Figure 1](#f1-medscimonit-22-1924){ref-type="fig"}). In subgroup analysis by ethnicity, the association was confirmed in Asians ([Figure 2B](#f2-medscimonit-22-1924){ref-type="fig"}), but not in whites (allele model: OR=1.23, 95%CI=1.01--1.48; homozygous model: OR=2.19, 95%CI=1.17--4.09; recessive model: OR=2.14, 95%CI=1.20--3.84, [Table 1](#t1-medscimonit-22-1924){ref-type="table"}).

No association observed between SNPs of *TFAM* and *VR22* and AD
----------------------------------------------------------------

A total of 3353 cases and 3089 controls from 11 studies were involved in the meta-analysis concerning rs1937 and rs2306604 of TFAM. No significant association was detected between the 2 SNPs and the risk of AD by the allele, the dominant, the recessive, or the homozygous model ([Figure 3](#f3-medscimonit-22-1924){ref-type="fig"}, [Table 2](#t2-medscimonit-22-1924){ref-type="table"}). In subgroup analysis, 9 of the studies were in whites and only 2 were in Asians. No clear correlation could be identified in the stratification by ethnicity ([Figure 4A, 4B](#f4-medscimonit-22-1924){ref-type="fig"}).

The association of rs10997691 and rs7070570 polymorphism of *VR22* and AD risk was investigated in 12 studies. No statistically significant correlation with AD was observed in the 4 models ([Figure 5](#f5-medscimonit-22-1924){ref-type="fig"}, [Table 3](#t3-medscimonit-22-1924){ref-type="table"}). Nevertheless, increased or decreased AD susceptibility was not observed in subgroup analysis by ethnicity in the studies of rs7070570 polymorphism ([Figure 4C](#f4-medscimonit-22-1924){ref-type="fig"}).

Publication bias
----------------

Publication biases of the articles were assessed by Begg's funnel plot and Egger's linear regression test on the metadata. The distribution of different studies on the funnel plot of each SNP appeared to be symmetrical, and no statistically significant asymmetry was detected by Egger's test. Hence, no evidence of publication bias for the correlation between the SNPs and AD susceptibility was found ([Tables 1](#t1-medscimonit-22-1924){ref-type="table"}[](#t2-medscimonit-22-1924){ref-type="table"}--[3](#t3-medscimonit-22-1924){ref-type="table"}).

Discussion
==========

We performed a systematic meta-analysis of case-control association studies for susceptibility to AD. We screened 3 candidate genes -- *CHAT*, *TFAM*, and *VR22* -- and their major polymorphisms. In the end, 51 studies of 16 446 cases and 16 057 controls were involved in the analysis. Our results showed that 2 SNPs of *CHAT* (rs2177369 and rs3810950) were significantly associated with AD susceptibility. We also observed ethnic differences for rs3810950 of *CHAT*, with A allele of rs3810950 in Asians as risk factors for AD, whereas rs1880676 and rs868750 of *CHAT*, rs1937 and rs2306604 of *TFAM*, and rs10997691 and rs7070570 of *VR22* did not contribute to AD risk.

*CHAT* encodes the enzyme responsible for the biosynthesis of ACh. CHAT protein is a marker used in evaluating the function of basal forebrain cholinergic cells and dementia severity in AD \[[@b45-medscimonit-22-1924],[@b46-medscimonit-22-1924]\]. Previous studies indicated that basal forebrain cholinergic neuron abnormalities are present very early in the course of AD, with altered expression of *CHAT* \[[@b47-medscimonit-22-1924],[@b48-medscimonit-22-1924]\]. Mutations or polymorphisms of *CHAT* are also suspected to be related to AD and its treatment \[[@b49-medscimonit-22-1924]\]. In agreement with previous results, we identified 2 SNPs of *CHAT* that contribute to the onset on AD.

*TFAM* locates in mitochondrial deoxyribonucleic acid (MTDNA) and encodes a key mitochondrial transcription factor that functions in mitochondrial DNA replication and repair. Mutations on *TFAM* can affect the function of mitochondria and contribute to the pathogenesis of AD. In accordance with the mitochondrial cascade hypothesis, the synergistic interactions between *TFAM* rs1937 and *APOE4* status have been reported to influence AD risk \[[@b50-medscimonit-22-1924]\], and rs2306604 A allele of *TFAM* was also found to be a moderate risk factor for AD \[[@b22-medscimonit-22-1924]\]. However, in the present study, we failed to confirm the results of Belin et al. and Zhang et al. \[[@b22-medscimonit-22-1924],[@b44-medscimonit-22-1924]\].

*VR22*, also known as CTNNA3, plays a role in cell-cell adhesion. *VR22* can bind directly to b-catenin, whereas b-catenin forms a complex with presenilin 1 (PSEN1) \[[@b51-medscimonit-22-1924]\], mutations of which cause familial cases of early-onset AD \[[@b52-medscimonit-22-1924]\]. Nonetheless, the 2 SNPs we enrolled in this meta-analysis failed to show significant associations with AD.

The principal results of the present study suggest that *TFAM* and *VR22* gene polymorphisms are not associated with risk of AD. All eligible case-control studies were included in this meta-analysis, including the most recent ones. However, there remain certain issues that need to be addressed in interpreting our results. Firstly, most of the subjects covered in our study were white (81.6% in cases and 76.0% in controls), which limits the general application of the results. As we have already observed, the association of AD with some SNPs can only be observed in certain ethnic groups. Further studies with more Asian and African subjects are recommended. Secondly, although it is statistically sufficient, the overall sample size for each SNP is still relatively small. Furthermore, individual genetic factors, the biological characteristics of tumors, and their interaction with the environment may influence cancer susceptibility and carcinogenesis. Because the diagnosis of most of the AD cases enrolled in the studies were based on diagnostic criteria rather than pathological examination, we cannot exclude that some cases might have been misdiagnosed, which further influences the results of this meta-analysis, and further work is required to minimize this effect.

Conclusions
===========

Rs2177369 and rs3810950 of *CHAT* are associated with AD susceptibility, but rs1880676 and rs868750 are not. Rs1937 and rs2306604 of *TFAM* and rs10997691 and rs7070570 of *VR22* are not significantly associated with AD risk.

Supplementary materials
=======================

###### 

Research terms.

  ------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  AD     Alzheimer Disease\[Mesh\] OR Alzheimer Disease\[tiab\] OR Alzheimer Sclerosis\[tiab\] OR Alzheimer Syndrome\[tiab\] OR Alzheimer Type Senile Dementia\[tiab\] OR Alzheimer-Type Dementia\[tiab\] OR Alzheimer Type Dementia\[tiab\] OR Alzheimer Type Dementia\[tiab\] OR Senile Dementia\[tiab\] OR Primary Senile Degenerative Dementia\[tiab\] OR Alzheimer Dementia\[tiab\] OR Alzheimer's Disease\[tiab\] OR Acute Confusional Senile Dementia\[tiab\] OR Presenile Dementia\[tiab\] OR Late Onset Alzheimer Disease\[tiab\] OR Focal Onset Alzheimer's Disease\[tiab\] OR Familial Alzheimer Disease\[tiab\] OR Presenile Alzheimer Dementia\[tiab\] OR Early Onset Alzheimer Disease\[tiab\] OR AD
  SNP    Polymorphism, Genetic\[Mesh\] OR Polymorphisms, Genetic\[tiab\] OR Genetic Polymorphism\[tiab\] OR Polymorphism\[tiab\] OR Genetic Polymorphisms\[tiab\] OR Polymorphism, Single Nucleotide\[Mesh\] OR Nucleotide Polymorphism, Single\[tiab\] OR Nucleotide Polymorphisms, Single\[tiab\] OR Single Nucleotide Polymorphisms\[tiab\] OR SNPs\[tiab\] OR Single Nucleotide Polymorphism\[tiab\] OR Polymorphisms, Single Nucleotide\[tiab\]
  CHAT   CHAT\[Mesh\] OR CHAT\[tiab\] OR CHOACTASE\[tiab\] OR Choline O-Acetyltransferase\[tiab\] OR Choline Acetylase\[tiab\] OR Choline Acetyltransferase\[tiab\] OR rs868750\[tiab\] OR rs3810950\[tiab\] OR rs2177369\[tiab\] OR rs1880676\[tiab\]
  TFAM   TFAM\[Mesh\] OR TFAM\[tiab\] TCF6\[tiab\] OR MTTF1\[tiab\] OR MTTFA\[tiab\] OR transcription factor A, mitochondrial\[tiab\] OR rs1937\[tiab\] OR rs2306604\[tiab\]
  VR22   CTNNA3\[Mesh\] OR CTNNA3\[tiab\] OR VR22\[tiab\] OR ARVD13\[tiab\] OR rs10997691\[tiab\] OR rs7070570\[tiab\]
  ------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Main characteristics of studies selected in the meta-analysis.

  Gene            SNP              First Author       Year         Country      Ethnicity    Case   Control   Case   Control                    
  --------------- ---------------- ------------------ ------------ ------------ ------------ ------ --------- ------ --------- ----- ----- ---- ---
  ***ChAT***      **rs1880676**    Ahn Jo             2006         Korea        Asian        316    264       211    99        6     193   69   2
  G\>A            Giedraitis       2009               Sweden       Caucasians   84           384    54        29     1         222   144   18   
  Harold          2003             UK                 Caucasians   68           85           34     25        9      49        33    3          
  Harold          2003             UK                 Caucasians   135          135          71     56        8      64        62    9          
  Harold          2003             UK                 Caucasians   194          209          105    77        12     127       79    3          
  Li              2008             Canada             Caucasians   690          681          386    256       48     364       275   42         
  Ozturk          2005             USA                Caucasians   1001         705          563    376       62     369       292   44         
  Reiman          2007             USA                Caucasians   853          550          478    329       46     303       206   41         
  **rs2177369**   Cook             2014               UK           Caucasians   381          370    158       207    105       162   164   55   
  G\>A            Cook             2005               UK           Caucasians   202          295    95        124    76        88    85    29   
  Cook            2005             UK                 Caucasians   202          295          29     85        88     76        124   95         
  Cook            2005             UK                 Caucasians   179          175          26     79        74     29        83    63         
  Piccardi        2007             Italy              Caucasians   158          118          44     75        39     40        57    21         
  Scacchi         2008             Italy              Caucasians   442          218          167    200       75     61        117   40         
  **rs3810950**   Ahn Jo           2006               Korea        Asian        316          264    211       99     6         192   70    2    
  G\>A            Cook             2005               UK           Caucasians   210          315    112       76     22        161   128   26   
  Gruenblatt      2008             Austria            Caucasians   120          456          63     45        12     268       164   24         
  Harold          2003             UK                 Caucasians   131          118          69     51        11     65        47    6          
  Kim             2004             Korea              Asian        246          561          171    61        14     419       133   9          
  Lee             2012             Korea              Asian        736          1386         505    205       26     1023      342   21         
  Mubumbila       2002             Germany & French   Caucasians   122          112          48     32        42     64        34    14         
  Ozturk          2005             USA                Caucasians   999          708          562    377       60     363       296   49         
  Schwarz         2003             Germany            Caucasians   242          143          139    94        9      83        52    8          
  Tang            2008             China              Asian        273          271          190    75        8      179       83    9          
  **rs868750**    Harold           2003               UK           Caucasians   119          116    72        39     8         83    31    2    
  G\>A            Harold           2003               UK           Caucasians   135          131    88        42     5         95    33    3    
  Harold          2003             UK                 Caucasians   209          222          129    75        5      130       84    8          
  Ozturk          2005             USA                Caucasians   989          706          628    322       39     476       217   13         
  ***TFAM***      **rs1937**       Alvarez            2008         Spain        Caucasians   300    183       277    23        0     158   23   2
  G\>C            Belin            2007               Swedish      Caucasians   423          313    339       78     6         251   55    7    
  Blomqvist       2005             Scotland           Caucasians   122          152          95     21        6      123       27    2          
  Blomqvist       2005             Sweden             Caucasians   204          174          156    43        5      143       30    1          
  Gunther         2004             --                 Caucasians   372          295          301    67        4      221       71    3          
  Zhang           2011             China              Asian        394          390          274    116       4      250       126   14         
  **rs2306604**   Alvarez          2008               Spain        Caucasians   300          183    93        151    56        50    99    34   
  A\>G            Belin            2007               Swedish      Caucasians   406          318    164       169    73        100   152   66   
  Giedraitis      2009             Sweden             Caucasians   85           400          29     41        15     146       200   54         
  Gunther         2004             --                 Caucasians   353          291          123    163       67     84        136   71         
  Zhang           2012             China              Asian        394          390          98     204       92     100       192   98         
  ***VR22***      **rs10997691**   Busby              2004         UK(I)        Caucasians   133    110       94     35        4     81    24   5
  T\>C            Busby            2004               UK(II)       Caucasians   108          104    79        25     4         85    19    0    
  Busby           2004             USA(I)             Caucasians   265          448          214    45        6      362       82    4          
  Busby           2004             USA(II)            Caucasians   94           90           68     23        3      71        18    1          
  **rs7070570**   Blomqvist        2004               Scotland     Caucasians   119          151    53        54     12        75    66    10   
  T\>C            Blomqvist        2004               Sweden       Caucasians   534          173    277       214    43        89    73    11   
  Busby           2004             UK(I)              Caucasians   145          121          72     63        10     54        58    9          
  Busby           2004             UK(II)             Caucasians   107          106          56     41        10     53        41    12         
  Busby           2004             USA(I)             Caucasians   266          423          141    110       15     226       172   25         
  Busby           2004             USA(II)            Caucasians   422          381          222    169       31     195       159   27         
  Cellini         2005             Italy              Caucasians   302          164          168    116       18     94        56    14         
  Kuwano          2006             Japan              Asian        348          328          23     155       170    33        122   173        

W -- wild allele; M -- mutation allele.

**Source of support:** Departmental sources

![Forest plots showed the relationship of the 4 SNPs -- rs1880676, rs2177369, rs3810950, and rs868750 -- in *CHAT* gene and the risk of AD. The odds ratio from each study is represented by a square and the confidence interval is indicated by error bars. The subtotal and overall odds ratio is signified by a rhombus.](medscimonit-22-1924-g001){#f1-medscimonit-22-1924}

![The forest plots of (**A**) *CHAT* rs1880676 and (**B**) *CHAT* rs3810950 by ethnicity. The odds ratio from each study is represented by a square and the confidence interval is indicated by error bars. The subtotal and overall odds ratio is signified by a rhombus.](medscimonit-22-1924-g002){#f2-medscimonit-22-1924}

![Forest plots showed the association of rs1937 and rs2306604 in *TFAM* gene with the risk of AD. The odds ratio from each study is represented by a square and the confidence interval is indicated by error bars. The subtotal and overall odds ratio is signified by a rhombus.](medscimonit-22-1924-g003){#f3-medscimonit-22-1924}

![The forest plots of (**A**) *TFAM* rs1937, (**B**) *TFAM* rs2306604, and (**C**) *VR22* rs7070570 by ethnicity. The odds ratio from each study is represented by a square and the confidence interval is indicated by error bars. The subtotal and overall odds ratio is signified by a rhombus.](medscimonit-22-1924-g004){#f4-medscimonit-22-1924}

![Forest plots showed the association of rs10997691 and rs7070570 in *VR22* gene with the risk of AD. The odds ratio from each study is represented by a square and the confidence interval is indicated by error bars. The subtotal and overall odds ratio is signified by a rhombus.](medscimonit-22-1924-g005){#f5-medscimonit-22-1924}

###### 

Meta-analysis of four polymorphisms in *ChAT* gene and AD susceptibility.

  Gene                     SNP                     Genetic model           OR (95% CI)         P~odds\ ratio~   Tau^2^     *I*^2^                  P~heterogeneity~        Ethnicity               Publication bias            
  ------------------------ ----------------------- ----------------------- ------------------- ---------------- ---------- ----------------------- ----------------------- ----------------------- ------------------- ------- -------
  *ChAT*                   rs1880676               **A** *vs.* G           1.01 (0.88--1.15)   0.896            0.017      51.6%                   0.044                   0.97 (0.86--1.11)       1.33 (0.96--1.83)   0.386   0.165
  **AA**+G**A** *vs.* GG   0.97 (0.85--1.11)       0.687                   0.010               30.4%            0.185      0.93 (0.83--1.03)       1.35 (0.95--1.94)       0.536                   0.239                       
  **AA** *vs.* GG          1.14 (0.74--1.74)       0.551                   0.170               57.0%            0.023      1.08 (0.70--1.66)       2.74 (0.55--13.76)      0.536                   0.095                       
  **AA** *vs.* GG+G**A**   1.16 (0.77--1.75)       0.474                   0.151               55.1%            0.029      1.11 (0.73--1.69)       2.54 (0.51--12.67)      0.536                   0.104                       
  rs2177369                **A** *vs.* G           1.13 (0.83--1.54)       0.439               0.133            88.6%      \<0.0001                1.13 (0.83--1.54)       --                      0.348               0.178   
  **AA**+G**A** *vs.* GG   1.14 (0.76--1.67)       0.531                   0.198               82.6%            \<0.0001   1.14 (0.76--1.69)       --                      0.452                   0.220                       
  **AA** *vs.* GG          **1.61 (1.07--2.43)**   **0.022**               0.185               72.6%            0.003      **1.61 (1.07--2.43)**   --                      1.000                   0.831                       
  **AA** *vs.* GG+G**A**   **1.53 (1.17--2.00)**   **0.002**               0.063               57.0%            0.040      **1.53 (1.17--2.00)**   --                      0.707                   0.659                       
  rs3810950                **A** *vs.* G           **1.23 (1.02--1.48)**   **0.033**           0.060            77.2%      \<0.0001                1.18 (0.90--1.55)       **1.23 (1.01--1.48)**   0.592               0.214   
  **AA**+G**A** *vs.* GG   1.16 (0.97--1.38)       0.105                   0.042               61.5%            0.008      1.09 (0.85--1.39)       1.20 (0.10--1.44)       0.592                   0.292                       
  **AA** *vs.* GG          **1.79 (1.12--2.86)**   **0.016**               0.346               72.5%            \<0.0001   1.44 (0.83--2.52)       **2.19 (1.17--4.09)**   0.858                   0.325                       
  **AA** *vs.* GG+G**A**   **1.76 (1.14--2.70)**   **0.010**               0.273               68.5%            0.001      1.45 (0.87--2.41)       **2.14 (1.20--3.84)**   1.000                   0.355                       
  rs868750                 **A** *vs.* G           1.21 (0.96--1.52)       0.113               0.027            49.3%      0.116                   1.21 (0.96--1.52)       --                      0.308               0.689   
  **AA**+G**A** *vs.* GG   1.19 (0.95--1.47)       0.125                   0.014               27.5%            0.247      1.19 (0.95--1.47)       --                      0.308                   0.628                       
  **AA** *vs.* GG          1.78 (0.86--3.70)       0.123                   0.229               41.1%            0.165      1.78 (0.86--3.71)       --                      0.734                   0.858                       
  **AA** *vs.* GG+G**A**   1.72 (0.87--3.37)       0.117                   0.161               33.1%            0.213      1.72 (0.87--3.37)       --                      0.734                   0.919                       

OR -- odds ratio; CI -- confidence intervals; In genetic model, the bold one means mutation allele.

###### 

Meta-analysis of two polymorphisms in *TFAM* gene and AD susceptibility.

  Gene                     SNP                 Genetic model      OR (95% CI)         P~odds\ ratio~   Tau^2^   *I*^2^              P~heterogeneity~    Ethnicity           Publication bias            
  ------------------------ ------------------- ------------------ ------------------- ---------------- -------- ------------------- ------------------- ------------------- ------------------- ------- -------
  *TFAM*                   rs1937              **C** *vs.* G      0.90 (0.90--1.17)   0.432            0.066    63.5%               0.018               0.94 (0.68--1.32)   0.76 (0.59--0.99)   1.000   0.395
  **CC**+G**C** *vs.* GG   0.88 (0.69--1.13)   0.310              0.045               49.2%            0.080    0.91 (0.66--1.26)   0.78 (0.58--1.05)   1.000               0.496                       
  **CC** *vs.* GG          0.86 (0.32--2.30)   0.759              0.817               57.3%            0.039    1.20 (0.43--3.34)   0.26 (0.09--0.80)   0.452               0.330                       
  **CC** *vs.* GG+G**C**   0.87 (0.33--2.30)   0.783              0.759               55.6%            0.046    1.22 (0.45--3.32)   0.28 (0.09--0.84)   0.452               0.335                       
  rs2306604                **G** *vs.* A       0.90 (0.79--1.0)   0.084               0.006            28.0%    0.235               0.87 (0.75--1.01)   0.98 (0.80--1.20)   0.462               0.308   
  **GG**+A**G** *vs.* AA   0.85 (0.70--1.02)   0.074              0.010               22.7%            0.270    0.78 (0.65--0.94)   1.04 (0.76--1.44)   0.462               0.387                       
  **GG** *vs.* AA          0.82 (0.65--1.04)   0.107              0.014               19.1%            0.293    0.79 (0.59--1.06)   0.96 (0.64--1.43)   0.806               0.192                       
  **GG** *vs.* AA+A**G**   0.89 (0.74--1.07)   0.200              0.000               0.0%             0.504    0.89 (0.70--1.11)   0.91 (0.66--1.26)   0.462               0.103                       

OR -- odds ratio; CI -- confidence intervals; In genetic model, the bold one means mutation allele.

###### 

Meta-analysis of two polymorphisms in *VR22* gene and AD susceptibility.

  Gene                     SNP                 Genetic model       OR (95% CI)         P~odds\ ratio~   Tau^2^   *I*^2^              P~heterogeneity~    Ethnicity           Publication bias           
  ------------------------ ------------------- ------------------- ------------------- ---------------- -------- ------------------- ------------------- ------------------- ------------------ ------- -------
  *VR22*                   rs10997691          **C** *vs.* T       1.22 (0.96--1.54)   0.106            0.0000   0.0%                0.436               1.22 (0.96--1.54)   --                 0.308   0.211
  **CC**+T**C** *vs.* TT   1.18 (0.91--1.54)   0.212               0.0000              0.0%             0.579    1.18 (0.91--1.54)   --                  0.308               0.098                      
  **CC** *vs.* TT          1.87 (0.72--4.87)   0.200               0.1895              19.1%            0.295    1.87 (0.72--4.87)   --                  0.308               0.183                      
  **CC** *vs.* TT+T**C**   1.82 (0.69--4.82)   0.229               0.2212              21.8%            0.280    1.82 (0.69--4.82)   --                  0.308               0.203                      
  rs7070570                **C** *vs.* T       0.99 (0.90--1.10)   0.903               0.0000           0.0%     0.959               1.00 (0.89--1.11)   0.99 (0.78--1.25)   0.902              0.930   
  **CC**+T**C** *vs.* TT   1.02 (0.89--1.17)   0.802               0.0000              0.0%             0.740    0.99 (0.86--1.14)   1.58 (0.91--2.75)   0.386               0.269                      
  **CC** *vs.* TT          1.07 (0.83--1.37)   0.617               0.0000              0.0%             0.780    1.00 (0.75--1.32)   1.41 (0.80--2.50)   0.536               0.710                      
  **CC** *vs.* TT+T**C**   0.94 (0.76--1.14)   0.513               0.0000              0.0%             0.828    1.00 (0.77--1.32)   0.86 (0.63--1.16)   0.711               0.326                      

OR -- odds ratio; CI -- confidence intervals; In genetic model, the bold one means mutation allele.
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